HCP
For help moving care forward.
Answers. Guidance. Resources.
Personalized and powered by more than six decades of innovation. All to help you and your patients feel confident in their care plan.
Access & Reimbursement
Streamlined assistance with benefits investigations, prior authorizations, appeals and claims.
Affordability
Personalized guidance on financial assistance programs that may be available, including foundation assistance options.
Education & Resources
Tools, resources and connection to advocacy groups that can help lend insight and understanding.
Logistics Support
Support with appointments, imaging sites and transportation services.
Access & Reimbursement
First things first: We’ll work closely with your office on the benefits verification and reimbursement process to help keep it streamlined and straightforward.
Dedicated Care Coordinators can help verify patient insurance benefits, including deductibles and copayments, and uncover possible coverage restrictions.
Our team can initiate prior authorization, educate you on any insurance requirements and provide resources for writing prior authorization letters. Once you submit, we’ll follow up on prior authorization status.
If an appeal is needed, our team will help you create custom appeal letters, gather documents and better understand how to move forward. Once you submit, we’ll check with the insurer on its status.
These downloadable resources give your practice comprehensive guidance and the forms you’ll need to expedite the reimbursement process.
Affordability
If covering the cost of the scan is a concern for patients, we can connect them to organizations that may be able to offer assistance. Use our Foundation Assistance Finder to share information that will help them find one that fits their needs.
Education & Resources
Patient guidance
With everything your patients are going through, it’s critical that they have easy access to education on what’s ahead for them. Consider sharing these brochures covering what to expect from their PYLARIFY® (piflufolastat F 18) injection scan and their enrollment in Lantheus Link.
Advocacy groups
Beyond the services we offer to patients, we have information on advocacy groups that specialize in their unique needs. They can be an invaluable source for connection to others who understand their situation.
Frequently asked questions
Patients prescribed a procedure consistent with approved usage of our diagnostic imaging agent are eligible to enroll. Caregivers to people with a diagnosis consistent with approved use are also welcome to enroll.
Ensure all enrollment form fields have been filled out by both you and your patient and submit the completed form via email or by faxing it to 844-339-8515.
Your patient’s Care Coordinator will reach out to both you and your patient to notify you that enrollment is complete and provide the necessary next steps.
When filling out the enrollment form, indicate your preferred communication methods in the appropriate form fields. You can update your communication preferences at any time.
The Patient Access Leader will be your point of contact for any questions or assistance with your patient’s care. The Care Coordinator will be an ongoing, designated point of contact for your patient, there to assist through every step leading up to and after their scan.
Lantheus Link can help your patient understand their insurance coverage and anticipated out-of-pocket expenses, as well as provide information on financial assistance organizations that may be able to help make their procedure more affordable.
Your patient’s Care Coordinator will conduct a benefits investigation to verify their insurance benefits, deductibles and copayments as well as any coverage restrictions. They will go over these findings during your patient’s onboarding call.
Reach out to your patient’s Care Coordinator immediately with the new insurance information so they can begin a benefits investigation into their new coverage.
Yes.
As part of our benefits investigation, we will determine whether your patient has transportation coverage through insurance. We can also provide information on other external transportation assistance options for getting them to and from their appointment.
You can use our scan facility locator to find an imaging site in your patient’s area and work with your patient’s Care Coordinator directly to determine if it is in their network.
Once a scan has been scheduled, your patient’s Care Coordinator will offer the option to sign up for scan reminders.
Your patient should call their imaging site or Care Coordinator to walk them through the necessary steps for rescheduling.
If you or your patients have any questions, you can contact our team Monday through Friday, 8:00 am to 8:00 pm ET, at 844-339-8514 or support@lantheuslink.com.
Logistics Support
We recognize that your patients already have a lot on their minds. We’re here to be a consistent through line leading up to their scan, giving them personalized assistance with appointment scheduling, confirmation and transportation.
Imaging site assistance
Use our scan facility locator or work with one of our Care Coordinators to help your patient find a convenient, in-network imaging site.
Appointment planning
On our onboarding call, we’ll walk your patient through how to schedule an appointment at the chosen facility. Our team can then set up reminders to be sent two days before the scan date or help with rescheduling.
Transportation arrangements
We can also help your patients verify any travel benefits through their insurance or find potential transportation options to and from their imaging site via our Foundation Assistance Finder.
What to expect
Support is many things. So Lantheus Link is, too.
Getting started with Lantheus Link is simple by design. Once enrolled, here’s what you and your patients can expect next.
Enrollment
Once signed by patients, forms can be submitted via email or faxed to 844-339-8515. With enrollment, we can provide in-network imaging center recommendations if you don’t have a preferred facility.
Benefits Investigation
After enrollment, we will conduct a benefits investigation and assist with prior authorizations, appeals and denials as needed.
Scheduling & Onboarding
We’ll call your patient to discuss benefits, guide them through scheduling an appointment and plan transportation logistics.
Reminders & Follow-ups
Patients can sign up for scan reminders, and, if necessary, we can assist with rescheduling. We’ll confirm scan completion and follow up if needed.
Enrollment
Once signed by patients, forms can be submitted via email or faxed to 844-339-8515. With enrollment, we can provide in-network imaging center recommendations if you don’t have a preferred facility.
Benefits Investigation
After enrollment, we will conduct a benefits investigation and assist with prior authorizations, appeals and denials as needed.
Scheduling & Onboarding
We’ll call your patient to discuss benefits, guide them through scheduling an appointment and plan transportation logistics.
Reminders & Follow-ups
Patients can sign up for scan reminders, and, if necessary, we can assist with rescheduling. We’ll confirm scan completion and follow up if needed.
It all starts here.
Complete the enrollment form with your patients and submit the form via fax at 844-339-8515 or email at support@lantheuslink.com.
Questions? We’re here to help Monday through Friday, 8:00 am to 8:00 pm ET, at 844-339-8514
or support@lantheuslink.com.
INDICATION
PYLARIFY (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:
- with suspected metastasis who are candidates for initial definitive therapy.
- with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
IMPORTANT SAFETY INFORMATION
Contraindications
None.
Warnings and Precautions
Risk of Image Misinterpretation
Imaging interpretation errors can occur with PYLARIFY imaging. A negative image does not rule out the presence of prostate cancer and a positive image does not confirm the presence of prostate cancer. The performance of PYLARIFY for imaging of patients with biochemical evidence of recurrence of prostate cancer seems to be affected by serum PSA levels. The performance of PYLARIFY for imaging of metastatic pelvic lymph nodes prior to initial definitive therapy seems to be affected by risk factors such as Gleason score and tumor stage. PYLARIFY uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes and in normal tissues. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended.
Hypersensitivity Reactions
Monitor patients for hypersensitivity reactions, particularly patients with a history of allergy to other drugs and foods. Reactions may be delayed. Always have trained staff and resuscitation equipment available.
Radiation Risks
Diagnostic radiopharmaceuticals, including PYLARIFY, expose patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration.
Adverse Reactions
The most frequently reported adverse reactions were headaches, dysgeusia and fatigue, occurring at rate of ≤2% during clinical studies with PYLARIFY. In addition, a delayed hypersensitivity reaction was reported in one patient (0.2%) with a history of allergic reactions.
Drug Interactions
Androgen deprivation therapy (ADT) and other therapies targeting the androgen pathway, such as androgen receptor antagonists, may result in changes in uptake of PYLARIFY in prostate cancer. The effect of these therapies on performance of PYLARIFY PET has not been established.
To report suspected adverse reactions for PYLARIFY, call 1-800-362-2668 or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
For important risk and use information about PYLARIFY Injection, please see Full Prescribing information.